M. Fässler

发表

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

D. Speiser, B. Ludewig, J. Neefjes, 2019, JAMA oncology.

BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.

D. Zillikens, W. Jochum, D. Bomze, 2020, Journal of the American Academy of Dermatology.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

R. Dummer, L. Risch, M. Risch, 2019, Journal of immunotherapy.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

R. Dummer, L. Risch, D. Speiser, 2019, Journal of Immunotherapy for Cancer.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

S. Güsewell, C. Ackermann, L. Flatz, 2018, Cancer management and research.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

David Bomze, Tobias L. Lenz, D. Bomze, 2019, European journal of cancer.

Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab

C. Schlapbach, M. Fässler, 2020, JAAD case reports.

Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibition

R. Dummer, D. Dietrich, C. Garbe, 2021 .

Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms

L. Borradori, H. Beltraminelli, M. Horn, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Successful treatment of refractory folliculitis decalvans with apremilast

N. Yawalkar, P. D. de Viragh, L. Pelloni, 2020, JAAD case reports.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

D. Bomze, T. Lenz, L. Flatz, 2019, European journal of cancer.